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Abstract
Background:  Prostate  cancer  is  the  ﬁrst  cause  of  mortality  related  to  malignancy  in  Mexican
men. Common  clinical  practice  has  to  be  evaluated  in  order  to  gain  a  picture  of  reality  apart
from the  guidelines.
Aim:  To  analyze  clinical  practice  among  urologists  in  Mexico  in  relation  to  prostate  cancer
management  and  to  compare  the  results  with  current  recommendations  and  guidelines.
Methods:  We  collected  the  data  from  600  urologists,  members  of  the  Sociedad  Mexicana  de
Urología, who  were  invited  by  email  to  answer  a  survey  on  their  usual  decisions  when  managing
controversial  aspects  of  prostate  cancer  patients.
Results:  Quinolones  were  the  most  common  antibiotic  used  as  prophylaxis  in  prostate  biopsy
(75.51%); 10--12  cores  were  taken  in  more  than  65%  of  prostate  biopsies;  and  18.27%  of  the
participants  performed  limited  pelvic  lymphadenectomy.  Treatment  results  showed  that  10.75%
of the  urologists  surveyed  preferred  radical  prostatectomy  as  monotherapy  in  high-risk  patients
with extraprostatic  extension  and  60.47%  used  complete  androgen  deprivation  in  metastatic
prostate cancer.
Conclusions:  There  are  many  areas  of  opportunity  for  improvement  in  our  current  clinical
practice  for  the  management  of  patients  with  prostate  cancer.
© 2016  Published  by  Masson  Doyma  México  S.A.  on  behalf  of  Sociedad  Mexicana  de  Urología.
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Encuesta  PCUMex:  Controversias  en  el  manejo  de  cáncer  de  próstata  entre  urólogos
mexicanos
Resumen
Antecedentes:  El  cáncer  de  próstata  es  la  primera  causa  de  mortalidad  relacionada  a  malig-
nidad en  hombres  mexicanos.  El  manejo  clínico  tiene  que  ser  evaluado  para  indagar  sobre  la
correlación  entre  la  práctica  diaria  y  las  guías  establecidas.
Objetivo:  Analizar  la  práctica  clínica  entre  urólogos  Mexicanos  acerca  del  manejo  en  cáncer
de próstata  y  evaluarlo  con  respecto  a  las  guías  y  recomendaciones.
Métodos:  Se  mandó  una  invitación  vía  e-mail  a  600  miembros  de  la  Sociedad  Mexicana  de
Urología para  contestar  una  encuesta  acerca  del  manejo  de  cáncer  de  próstata.
Resultados:  El  antibiótico  más  usado  para  proﬁlaxis  en  la  biopsia  de  próstata  fueron  las
quinolonas  (75.51%);  acerca  de  la  biopsia  de  próstata,  65%  de  la  población  tomaba  entre  10-12
muestras; 18.27%  de  los  participantes  realizaban  una  linfadenectomia  limitada.  10.75%  de  los
encuestados  preferían  una  prostatectomía  radical  como  monoterapia  en  los  pacientes  de  alto
riesgo con  extensión  extraprostática  y  64.47%  de  los  urólogos  usaron  el  bloqueo  androgénico
completo  en  el  cáncer  de  próstata  metastásico.
Conclusiones:  Hay  múltiples  áreas  de  oportunidad  para  mejorar  en  la  actual  práctica  clínica  en
el manejo  de  pacientes  con  cáncer  de  próstata.
© 2016  Publicado  por  Masson  Doyma  México  S.A.  en  nombre  de  Sociedad  Mexicana  de  Urología.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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introduction
rostate  cancer  (CaP)  is  one  of  the  most  important  health-
are  problems  for  adult  men  in  Mexico.  In  2013,  this  common
alignancy  was  the  leading  cause  of  death  associated  with
ancer  in  men  in  Mexico.1 In  2014,  there  were  233,000  new
ases  of  patients  with  CaP.  Mortality  was  about  13  deaths
er  100,000  men.2 CaP  is  a  very  common  concern  in  the
aily  clinical  practice  of  every  urologist  and  its  adequate
anagement  and  treatment  are  crucial  for  increasing  life
xpectancy  and  quality  of  life  in  the  patients  with  this  dis-
ase.
To  the  best  of  our  knowledge,  there  are  no  reports  in  Mex-
co  that  evaluate  the  clinical  practice  and  decision-making
f  Mexican  urologists,  and  therefore  it  is  necessary  to  create
tudies  that  assess  these  aspects.
The  aim  of  this  article  was  to  analyze  clinical  practice
mong  urologists  in  Mexico  in  relation  to  controversial  sub-
ects  of  CaP  management  and  to  compare  the  results  with
he  national  and  international  recommendations.
ethods
n  online  survey  called  Práctica  Clínica  de  Urólo-
os  de  México  (PCUMex)  (Clinical  Practice  of  Mexi-
an  Urologists)  was  employed.  This  questionnaire  was
vailable  on  the  Survey  Monkey  website  (https://es.
urveymonkey.com/r/BKVXPFV).  An  invitation  email  was
ent  to  600  physicians  belonging  to  the  national  urologic
ociety,  Sociedad  Mexicana  de  Urología  (SMU). Two  reminder
mails  were  sent  after  one  and  2  weeks.  The  website  was
pen  from  April  to  May  2013  and  there  was  only  one  oppor-
unity  to  ﬁll  out  the  questionnaire  per  email  link.  Website
ccess  was  anonymous  and  no  traceable  or  personal  data
s
s
s
aas  gathered.  The  study  included  20  multiple  choice  closed-
nded  questions.
The  results  were  evaluated  through  a  descriptive  analysis
nd  a  critical  evidence-based  discussion.
esults and discussion
 total  of  102  physicians  participated  in  the  survey;  100
98%)  were  men  and  2  (2%)  were  women.  Table  1  describes
he  rest  of  the  demographic  and  academic  variables.
uestion  1:  bowel  preparation  as  antibacterial
rophylaxis  in  prostate  biopsy
owel  preparation  or  a  cleansing  enema  before  biopsy
ecrease  the  amount  of  feces  in  the  rectum  and  poten-
ially  enable  better  visualization  for  prostate  imaging.  In  our
opulation,  most  of  the  clinicians  used  a  rectal  enema  as
re-biopsy  preparation  (Fig.  1).  According  to  the  Canadian
rology  Association  (CUA)  guidelines,  the  effect  of  bowel
reparation  on  infection  is  debatable  and  it  is  a  practice  that
as  been  abandoned  due  to  patient  cost,  inconvenience,  and
he  lack  of  data  supporting  the  effect  of  prophylaxis.3 In
act,  some  authors  suggest  that  the  enema  increases  the
dds  of  infection  because  it  liquidizes  the  feces.4 Lindert
ompared  the  incidence  of  bacteriuria  and  bacteremia  in
atients  with  or  without  enema  use.  The  results  showed
hat  the  enema  reduced  the  incidence  of  bacteremia,  but
t  was  asymptomatic  in  most  of  the  cases.5 In  an  alternate
tudy,  a  clear-ﬂuid  diet  and  the  use  of  intestinal  preparation
howed  no  signiﬁcant  difference  in  the  rate  of  post-biopsy
epsis.6 We  conclude  that  bowel  preparation  has  no  impact
s  antibacterial  prophylaxis  and  can  be  eliminated  in
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Table  1  Demographic  information  (n  [%]).
Working  area  Urban  area  100  (98)
Rural area 2  (2)
Training level Residents 14  (13.7)
Urologists  48  (47.1)
Urologists  with  a  subspecialty  40  (39.2)
Health sector  practice  Private  88  (86.3)
Public 63  (61.8)
Academic actualization  method  National  academic  conferences  90  (88.2)
National urology  scientiﬁc  meetings  78  (76.5)
International  conferences  and  scientiﬁc  meetings  70  (68.6)
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628559Number of respondents
ibacterial  prophylaxis  in  prostate  biopsy.
Table  2  First-line  antibiotic  prophylaxis  in  prostate  biopsy.
Antibiotic  Number  of
respondents
Percentage
Ciproﬂoxacin  42  42.86%
Levoﬂoxacin  27  27.55%
Piperacillin/tazobactam  8  8.16%
Trimethoprim/
sulfamethoxazole
5  5.10%
Oﬂoxacin  5  5.10%
Gentamicin  4  4.09%
Cephalexin  3  3.06%
Fosfomycin  2  2.04%
Ceftriaxone  1  1.02%
Clindamycin  1  1.02%
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rFigure  1  Bowel  preparation  as  ant
clinical  practice  to  avoid  inconvenience  to  the  patients,
given  that  no  proven  beneﬁt  has  been  demonstrated.
Question  2:  ﬁrst-line  antibiotic  prophylaxis  in  prostate
biopsy
Antibiotic  prophylaxis  is  suggested  for  all  patients  before
biopsy.  The  medication  has  to  be  effective  for  the  ﬂora
in  the  rectum  and  genitourinary  tract,  especially  Gram-
negative  bacteria.  Quinolones  are  the  treatment  of  choice
according  to  the  CUA  and  European  Association  of  Urology
(EAU)  guidelines.3,7 The  recommendations  suggest  the  appli-
cation  of  antibiotic  1-h  prior  to  the  biopsy  and  2--3  days
after  the  procedure.  In  the  Mexican  population  and  other
countries,  such  as  India  or  in  Africa,  the  rates  of  resistance
to  quinolones  are  high.8,9 The  data  in  our  institution  showed
that  quinolone  resistance  could  be  as  high  as  61%.  In  Mexico,
the  reported  resistance  ranges  from  24  to  50%,  which  rules
out  these  antibiotics  as  a  viable  option.10
In  our  survey,  the  data  showed  that  74  (75.51%)  partic-
ipants  used  quinolones  as  ﬁrst-line  antibiotic  prophylaxis
(Table  2).  Even  though  they  may  be  following  the  advice  of
international  guidelines,  the  rates  of  infective  complications
due  to  the  increased  resistance  to  ﬂuoroquinolones  after
prostate  biopsy  are  2.4--7.5%.11 In  our  institution,  a  pre-
vious  study  encouraged  the  use  of  a  single  dose  of
piperacillin/tazobactam  before  the  biopsy  as  prophylaxis  in
prostate  biopsy  due  to  high  resistance  to  narrower-spectrum
antibiotics.11 According  to  recent  results  from  our  insti-
tution  that  are  awaiting  publication,  the  best  options  at
our  hospital  might  be:  amikacin,  ertapenem,  fosfomycin,
and  nitrofurantoin.  We  conclude  that  quinolones  should  not
be  used  as  antibiotic  prophylaxis  and  the  decision-making
should  be  tailored  according  to  local  resistance  patterns.
u
h
o
cTotal  98  100.00%
uestion  3:  number  of  cores  in  the  ﬁrst  transrectal
rostate biopsy  diagnosing  prostate  cancer
here  is  no  consensus  on  the  number  of  cores  and  their
ocation  in  prostate  cancer  biopsy.  Originally  the  standard
extant  biopsy  scheme  consisted  of  6  cores  (one  from  the
ase,  mid  zone,  and  apex,  bilaterally),  but  this  pattern  has
roduced  false  negatives  and  on  average,  30%  of  the  can-
ers  are  missed  by  the  sextant  biopsy  scheme.12 The  survey
esults  showed  that  3  (3.23%)  of  the  urologists  continued  to
se  this  inefﬁcient/obsolete  scheme  (Fig.  2). On  the  other
and,  EAU  recommendations  state  that  for  prostate  volumes
f  30--40  mL,  more  than  8  cores  should  be  sampled.  The
urrent  recommendation  is  that  10--12  core  biopsies  is  the
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Table  3  Type  of  pelvic  lymphadenectomy  in  radical  retrop-
ubic prostatectomy  surgery  in  low/medium  risk  prostate
cancer.
Anatomic  extension  Number  of
respondents
Percentage
Obturator  fossa  +  internal
Iliac
41  44.09%
Obturator  fossa  +  internal
iliac  +  common  iliac
25  26.88%
Obturator  fossa  17  18.27%
None  7  7.53%
Obturator  fossa  +  internal
iliac  +  common
Iliac  +  presacral
3  3.23%
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pFigure  2  Number  of  cores  in  the  ﬁrst  transr
deal  approach  and  our  results  showed  that  more  than  65%
f  the  participants  adequately  followed  this  advice.7 In  fact,
he  Mexican  guidelines  suggest  that  in  a  prostate  biopsy,  the
hysician  should  take  at  least  10--12  cores  and  the  number
an  be  higher  for  very  large  prostate  volumes.13 A  percent-
ge  of  our  population  (11.85%)  took  more  than  12  cores
n  the  biopsy.  However,  taking  more  than  12  cores  added
o  signiﬁcant  beneﬁt  to  the  diagnosis  of  prostate  cancer
Fig.  2).14 Five  participants  took  cores  from  the  transition
one.  According  to  the  literature,  the  transition  zone  should
e  biopsied  in  men  with  a  gland  size  greater  than  50  mL,
ecause  the  additional  yield  in  cancer  detection  is  15%.15
e  reiterate  that  in  the  ﬁrst  transrectal  prostate  biopsy,
he  number  of  cores  cannot  be  less  than  10  or  more  than  16.
uestion  4:  pelvic  lymphadenectomy  in  radical
etropubic  prostatectomy  surgery  in  low/medium
rostate cancer  risk
elvic  lymphadenectomy  (PL)  remains  the  most  accurate
rocedure  for  detecting  nodal  involvement  and  gives  more
ccurate  information  for  prognosis  after  analyzing  the  num-
er  of  lymph  nodes  involved  and  the  capsule  ruptured  by
he  malignancy.16 Table  3  shows  that  7  participants  (7.53%)
id  not  perform  lymphadenectomy,  whereas  86  subjects
92.47%)  performed  PL  in  at  least  one  anatomic  zone.
he  decision  to  carry  out  lymphadenectomy  is  based  on
he  likelihood  of  metastasis  in  the  lymph  nodes  and  the
ercentage  of  patients  at  low-risk,  medium-risk,  and  high-
isk  for  the  possibility  of  metastasis  is  <5%,  3.7-20-1%,
nd  15--40%,  respectively.7 There  is  a  consensus  that  the
pproach  to  lymph  node  dissection  in  low-risk  patients  is  not
ndicated.7 A  minimum  sector  of  our  survey  sample  did  not
emove  lymph  nodes.  This  is  probably  because  many  of  the
atients  are  categorized  as  medium-risk.  However,  practice
n  regard  to  surgical  decisions  is  controversial  in  this  group
f  patients.  The  EAU  and  Mexican  guidelines  recommend
elvic  lymphadenectomy  in  medium/high-risk  subjects.7,13
he  American  Urological  Association  (AUA)  states  that  PL
b
(
a
tTotal 93  100.00%
s  generally  reserved  for  high-risk  patients.17 In  summary,
he  PL  in  medium-risk  subjects  is  indicated  if  the  risk  for
ositive  nodes  is  >5%.7 Concerning  PL  extension,  obturator
ossa  lymphadenectomy  is  not  sufﬁcient,  because  it  will  miss
pproximately  50%  of  metastases.18 Hence,  the  iliac  region
ust  be  included.
uestion  5:  penile  rehabilitation  after  radical
etropubic prostatectomy
rectile  dysfunction  after  radical  retropubic  prostatectomy
RRP)  is  a  common  consequence  of  the  surgery.  The  erec-
ile  function  rates  are  from  11  to  87%  after  RRP.19 The
actors  that  have  an  impact  on  the  recovery  of  erec-
ile  function  after  radical  prostatectomy  are:  patient  age,
reoperative  potency  status,  and  the  ability  to  preserve
15oth  neurovascular  bundles. In  our  sample,  84  physicians
90.32%)  prescribed  a  phosphodiesterase  type-5  inhibitor
nd  2  urologists  (2.16%)  prescribed  intracavernous  injec-
ions  (ICIs)  for  penile  rehabilitation  (Fig.  3).  The  EAU
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fter  radical  retropubic  prostatectomy.
cancer-speciﬁc  survival  of  80%.26 It  is  possible  that  surgery
will  become  the  cornerstone  of  integrated  treatment,  in  the
form  of  cytoreductive  therapy  and  its  potential  combina-
tion  with  adjuvant  radiotherapy.  If  they  are  carried  out  the
other  way  around,  they  will  not  provide  the  same  beneﬁt
and  will  lower  the  chances  of  salvage  surgery,  because  of
greater  technical  demands  and  risk.  Furthermore,  adjuvant
radiotherapy  focuses  on  a  smaller  area  when  compared  with
primary  radiotherapy.
Nine  participants  utilized  radiotherapy  as  monotherapy,
but  current  medical  evidence  suggests  that  this  sort  of
Table  4  Treatment  in  patients  with  high-risk  prostate  can-
cer with  extraprostatic  extension.
Treatment  Number  of
respondents
Percentage
Radiation  therapy  +  androgen
deprivation
27  29.03%
Androgen  deprivation  21  22.58%
Radical  retropubic
prostatectomy  +  radiation
therapy
13  13.98%
Radiation  therapy  9  9.68%
Open Radical  retropubic
prostatectomy
7  7.53%
Radical  retropubic
prostatectomy  +  androgen
deprivation
6  6.46%
Laparoscopic/robotic-assisted
laparoscopic  radical
retropubic  prostatectomy
3  3.23%
Radical  retropubic
prostatectomy  +  adjuvant
neo-adjuvant  androgen
deprivation
3  3.23%
Radiation
therapy  +  chemotherapy  +
androgen  deprivation
2  2.14%
Chemotherapy  +  androgen 1  1.07%Figure  3  Penile  rehabilitation  a
guidelines  specify  that  this  topic  remains  controver-
sial  because  placebo  studies  have  not  shown  a  deﬁnite
beneﬁt  when  compared  with  daily  administration  of  var-
denaﬁl  or  sildenaﬁl  or  compared  with  on-demand  sildenaﬁl
administration.7 In  contrast  to  this  information,  there  is  a
previous  trial  that  suggests  that  10  and  20  mg  vardenaﬁl
doses  on  demand  were  superior  to  placebo  when  eval-
uated  with  the  International  Index  of  Erectile  Function
(IIEF).20 Other  trials  showed  that  a  daily  dose  of  tadalaﬁl
was  more  effective  than  placebo  or  tadalaﬁl  on  demand,21
but  another  trial  comparing  a  nighttime  dose  of  sildenaﬁl
versus  on-demand  doses  did  not  ﬁnd  any  differences.22 It
has  been  suggested  that  ICI  is  efﬁcacious  in  improving  erec-
tile  function,  compared  with  patients  that  do  not  receive
any  treatment.23 Some  trials  suggest  that  the  range  of
ICI  effectiveness  is  30--55%,  and  that  the  role  of  these
drugs  in  combination  with  sildenaﬁl  can  decrease  sildenaﬁl
failures.24 With  the  evidence  that  is  available,  while  waiting
for  higher  levels  of  evidence,  the  use  of  phosphodiesterase
type-5  inhibitors  is  the  potential  ﬁrst-line  treatment  in
penile  rehabilitation  after  RRP,  with  ICI  as  second-line  treat-
ment  in  patients  that  do  not  respond  to  oral  medications  or
that  undergo  non-nerve-sparing  surgery.
Question  6:  treatment  in  patients  with  high-risk
prostate cancer  with  extraprostatic  extension
Table  4  shows  our  ﬁndings.  Fifty-two  of  the  participants  used
2  or  more  treatment  modalities  and  40  out  of  93  participants
included  radiation  therapy  as  treatment  for  this  group  of
patients.  Only  10.75%  of  the  contestants  decided  upon  rad-
ical  prostatectomy  as  monotherapy  in  the  management  of
these  patients  (Table  4).  However,  we  have  to  acknowledge
the  likelihood  of  future  multimodality  therapy  in  high-risk
cancer  patients  initially  treated  with  monotherapy.7 The
use  of  radical  prostatectomy  as  monotherapy  has  currently
decreased  due  to  the  recognition  that  prostatectomy  alone
is  insufﬁcient.15 Recent  trials  have  demonstrated  that  the
use  of  neo-adjuvant  androgen  deprivation  before  prosta-
tectomy  does  not  provide  beneﬁt  compared  with  surgery
alone.25 On  the  other  hand,  surgery  is  now  being  performed
as  the  ﬁrst  stage  of  multimodality  therapy.  For  example,  the
combination  of  radical  prostatectomy  (RP)  plus  early  adju-
vant  hormone  therapy  has  been  shown  to  achieve  a  10-year
deprivation
Watchful  waiting  1  1.07%
Total 93  100.00%
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therapy  alone  is  inefﬁcient  and  that  results  are  more  effec-
tive  when  combined  with  androgen  deprivation  therapy
(ADT).7 In  patients  who  are  not  candidates  for  radical
treatment,  EAU  guidelines  indicate  that  early  androgen
deprivation  may  improve  survival,  using  surgical  castration
or  hormone  therapy,  mainly  with  luteinizing  hormone-
releasing  hormone  agonists  or  antagonists,  which  are  all
deemed  to  be  equally  effective.7
In  summary,  the  current  tendency  for  treatment  of  high-
risk  patients  with  extraprostatic  extension  is  multimodality
therapy  with  surgery  as  the  initial  step  of  this  treatment.
Question  7:  ﬁrst-line  treatment  in  patients  with
metastatic prostate  cancer
The  National  Comprehensive  Cancer  Network  (NCCN)  estab-
lishes  that  ADT  is  the  gold  standard  for  men  with  metastatic
prostate  cancer.27 According  to  EUA  guidelines  on  the  mul-
tiple  therapeutic  approaches  for  ADT,  the  gold  standard
is  surgical  castration,  such  as  bilateral  orchiectomy.7 Few
surveyed  urologists  preferred  surgical  management  and
the  majority  of  the  urologists  used  hormone  therapy
(Table  5).  Surgical  management  is  the  gold  standard,  but  the
luteinizing  hormone-releasing  hormone  (LHRH)  agonists  and
antagonists  are  equally  effective.27 Consequently,  the  ten-
dency  is  for  surgical  castration  to  be  used  less  frequently.
Antiandrogen  monotherapy  is  not  considered  as  effective
as  LHRH  blockade  or  surgical  castration  by  most  guide-
lines.  From  our  sample,  only  3  physicians  used  antiandrogen
monotherapy.  Nowadays,  LHRH  agonists  are  the  main  form
of  ADT  used  in  conjunction  with  early  antiandrogens  to  pre-
vent  the  ﬂare  effect;  in  our  population  this  was  the  most
common  therapy.  One  of  the  main  problems  is  the  cost-
effectiveness  of  long-term  hormone  therapy.  According  to
a  previous  report,  medical  castration  with  combined  andro-
gen  blockade  is  the  least  economically  attractive  strategy,
when  compared  with  surgical  castration.28 We  consider  that
the  use  of  orchiectomy  in  Mexico  is  below  the  expected
frequency,  possibly  due  to  the  conditions  of  the  Mexi-
can  economy.  Surgical  castration  is  a  potential  option  that
should  be  contemplated.
Table  5  First-line  treatment  in  patients  with  metastatic
prostate  cancer.
Treatment  Number  of
respondents
Percentage
Complete  androgen  blockade
(central  +  peripheral)
52  60.47%
Central  androgen  blockade
using  luteinizing
hormone-releasing  agonist
hormone
16  18.60%
Central  androgen  blockade
using  luteinizing
hormone-releasing
antagonist  hormone
9  10.47%
Bilateral  orchiectomy  6  6.98%
Peripheral  androgen  blockade  3  3.48%
Total  86  100.00%
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onclusions
here  are  numerous  opportunities  for  improvement  in
egard  to  the  clinical  practice  of  urologists  that  manage
atients  with  prostate  cancer  in  Mexico.  Many  urologists
ollow  international  recommendations,  but  these  are  not
djusted  to  Mexican  patients  and  their  environment,  as  is
he  case  with  antibiotic  prophylaxis  or  metastatic  disease
anagement.  Given  that  prostate  cancer  is  a  prevalent
alignant  disease,  attention  must  be  guided  towards  the
articular  needs  of  our  country.  In  addition,  physicians  must
onstantly  update  their  knowledge  to  avoid  practices  that
o  not  beneﬁt  the  patient,  such  as  an  excessive  num-
er  of  cores  in  ﬁrst  prostate  biopsies,  over-extensive  or
imited  lymphadenectomy,  or  incomplete  treatment  in  high-
isk  prostate  cancer  patients  presenting  with  extraprostatic
xtension.
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